Scaling to meet demand.
A couple of years ago, I switched to a new type of blood glucose monitoring. It was a bit of a learning curve (sometimes literally). Trying to manage your diabetes with a lag time of 30-60 mins in the readings is difficult and makes you bump up and down (as your insulin also has a lag time) until you get the hang of it.
But there have been other problems.
Firstly, the app has been horrific. It was advertised as working with most android phones with a modern enough version and NFC turned on. However, it kept bricking sensors. And I mean, within half an hour of activating them, they would be bricked. Each sensor cost about £50. Gradually, the phones listed as supported on Google Play reduced to just a Samsung Galaxy (suggesting that the pool for testing had been limited) and as I was using either a Nexus or Pixel at the time, I thought it was weird that it wouldn’t even work with Google’s reference hardware.
Secondly, supply. When the product was first released, it was rare as hens’ teeth. In a sense, this was to be expected, it was an affordable way to get beyond fingerprick testing and it was from an established, good company (I always swore by freestyle over bayer as their test strips seemed to fail less often and needed a lot less blood).
However, the growth of the customer base hasn’t been matched with an increase in manufacturing capability. For the past six months, the website has shown problems with stocks and supplies.
There are big reasons why this is a problem:
1) It’s expensive to stockpile. At 50 quid a pop, I don’t like dropping hundreds of quid on medical supplies.
2) You can’t stockpile because stocks are too low and they’re restricting orders to two per person per 25 days
3) Each sensor lasts 14 days, but the delivery time quoted is longer than 14 days.
So, what they’re doing is making sure that ordering their product becomes something you have to think about. You can’t set up a subscription of two a month, you have to remember. I tend to remember when I put a sensor in my arm and notice that that was the last one.
I can get hold of other test strips, but they haven’t been on my prescription for years. It’s more faff. And it is more faff because a company has let their production ability fall behind their marketing.
I’m trying to say, I rely on this technology. It has improved my life a lot, but the supply troubles are really worrying. It is hard to imagine this getting any better as more areas of the UK allow Freestyle Libre on prescription and Brexit potentially screws up the supply chain.
As I mentioned in my first blog on the company, the most frustrating thing is that they don’t reply on social media. They don’t email you to say there are supply problems or iterate the product to prevent ebbs and flows in demand from people stockpiling (by allowing you to set up a monthly subscription).
I wish organisations like Diabetes UK and Input Diabetes would put a bit more pressure on Abbott to up their game in terms of dealing with customers. We pay a pretty penny for their product, and we are rewarded with fragile apps, fragile supply chains and more life admin for a disease that is already a X2 multiplier of life admin. I also wish another manufacturer would bring a flash glucose sensor to market so that Abbott might have to start behaving like they needed to compete to keep their customers.










